IMUGENE LIMITED — Board/Management Information 2019

Dec 4, 2019

ASX Announcement

==> picture [116 x 42] intentionally omitted <==

Imugene appoints Dr Rebecca Auer, of the Ottawa Hospital to Oncolytic Virotherapy Scientific Advisory Board

---

Sydney, Australia, 05 December 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Dr Rebecca Auer, MD MSc FRCSC, Associate Professor, Department of Surgery and Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine University of Ottawa; Surgical Oncologist, The Ottawa Hospital; Tier 2 Clinical Research Chair in Perioperative Cancer Therapeutics University of Ottawa, to its newly formed oncolytic virotherapy (OV) Scientific Advisory Board (SAB).

As a Surgeon-Scientist, Dr. Auer heads a research laboratory and is the principle investigator in related clinical trials. Her translational research program focuses on understanding the promotion of metastatic disease in the perioperative period, following surgical stress. In particular she is studying novel perioperative cancer therapies, including oncolytic viruses, cancer vaccines and targeted therapies, which inhibit the formation of metastases postoperatively.

OVs are designed to both selectively kill tumour cells and deliver a potent payload, which together activate the immune system against cancer cells, with the potential to improve clinical response and survival. Oncolytic virotherapy has the potential to transform oncology.

Imugene’s M.D. & CEO, Ms Leslie Chong said, “It is a great honour for Imugene to have such a distinguished physician and scientist join our team. Dr. Auer has devoted her career to exploring scientific discoveries for the benefit of cancer sufferers.”

For further information please contact:

Leslie Chong Managing Director and Chief Executive Officer T: +61 458 040 433 E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

About Dr. Rebecca Auer

Dr. Rebecca Auer is a Surgical Oncologist and translational researcher studying the impact of surgery on the immune system and subsequent cancer recurrence. In her laboratory the focus is to develop innovative cancer therapeutics that can be administered during the perioperative period and to translate these therapies to the clinic. With three active clinical studies of perioperative cancer therapies, Dr. Auer aims to improve cancer outcomes for all patients who undergo invasive cancer surgeries.

After receiving the Gold Medal in Medicine at Queen's University, Dr. Auer moved to Ottawa to undertake her residency in General Surgery while concurrently completing an MSc in Biochemistry at the University of Ottawa. Following this, she completed a fellowship in Surgical Oncology at the Memorial Sloan-Kettering Cancer Centre in New York where she served as Chief Fellow for the Department of Surgery. In 2007, Dr. Auer was recruited to Ottawa and currently holds the position of Surgical Oncologist at the Ottawa Hospital, Scientist at the Ottawa Hospital Research Institute (OHRI) and Assistant Professor in the Department of Surgery and the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa.

Dr. Auer is a pioneer in the field of perioperative cancer therapeutics. Her research is among the first to explore the mechanisms responsible for the promotion of cancer growth and metastases that occurs after surgery. Her work has clarified a mediating role for Natural Killer cells and Myeloid Dervides Supressor Cells in the immune suppression induced by surgical stress and is currently elucidating pathways involved in this effect. Moreover, she has developed and translated four non-traditional immune therapies from her laboratory discoveries to clinical trials, including perioperative low molecular-weight heparin, PDE-5 inhibitors and oncolytic viruses.

Dr. Auer is a leader in the field of Surgical Oncology. She serves as the Chair of the Rectal Disease Oncology Group for the Canadian Cancer Trials Group and is a executive member of the Clinical Trials Committee. She is on the executive of the Canadian Society of Surgical Oncology and is a member of the US Rectal-Anal Task Force and of the International Committee of the Society of Surgical Oncology. Her research program is a member of the Ontario Institute of Cancer Research Immuno-oncology Translational Research Initiative, the Canadian Oncolytic Virus Consortium, and BioCanRx, the National Center of Excellence in Biotherapy.

2

IMUGENE LIMITED ACN 009 179 551

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

3

IMUGENE LIMITED ACN 009 179 551